These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 16307630)
21. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Turner BJ; Laine C; Lin YT; Lynch K Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826 [TBL] [Abstract][Full Text] [Related]
22. Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Lapeyre-Mestre M; Llau ME; Gony M; Navel AM; Bez J; Grau M; Montastruc JL Drug Alcohol Depend; 2003 Dec; 72(3):297-303. PubMed ID: 14643947 [TBL] [Abstract][Full Text] [Related]
23. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Burns L; Randall D; Hall WD; Law M; Butler T; Bell J; Degenhardt L Addiction; 2009 Aug; 104(8):1363-72. PubMed ID: 19549053 [TBL] [Abstract][Full Text] [Related]
24. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. Soyka M; Apelt SM; Lieb M; Wittchen HU J Clin Psychopharmacol; 2006 Dec; 26(6):657-60. PubMed ID: 17110826 [TBL] [Abstract][Full Text] [Related]
26. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759 [TBL] [Abstract][Full Text] [Related]
27. [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice]. Dupouy J; Bez J; Barsony J; Oustric S; Lapeyre-Mestre M Therapie; 2013; 68(3):155-61. PubMed ID: 23886460 [TBL] [Abstract][Full Text] [Related]
28. Long-term consequences of acute pain for patients under methadone or buprenorphine maintenance treatment. Bounes V; Palmaro A; Lapeyre-Mestre M; Roussin A Pain Physician; 2013; 16(6):E739-47. PubMed ID: 24284855 [TBL] [Abstract][Full Text] [Related]
29. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077 [TBL] [Abstract][Full Text] [Related]
30. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial. Chawarski MC; Mazlan M; Schottenfeld RS Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145 [TBL] [Abstract][Full Text] [Related]
31. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Kakko J; Heilig M; Sarman I Drug Alcohol Depend; 2008 Jul; 96(1-2):69-78. PubMed ID: 18355989 [TBL] [Abstract][Full Text] [Related]
32. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. Giacomuzzi SM; Ertl M; Kemmler G; Riemer Y; Vigl A ScientificWorldJournal; 2005 May; 5():452-68. PubMed ID: 15925962 [TBL] [Abstract][Full Text] [Related]
33. [Buprenorphine or methadone for detoxification of young opioid addicts?]. Ebner R; Schreiber W; Zierer C Psychiatr Prax; 2004 Nov; 31 Suppl 1():S108-10. PubMed ID: 15570521 [TBL] [Abstract][Full Text] [Related]
34. Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. Torrington M; Domier CP; Hillhouse M; Ling W J Addict Dis; 2007; 26(3):93-9. PubMed ID: 18018812 [TBL] [Abstract][Full Text] [Related]
35. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Hickman M; Steer C; Tilling K; Lim AG; Marsden J; Millar T; Strang J; Telfer M; Vickerman P; Macleod J Addiction; 2018 Aug; 113(8):1461-1476. PubMed ID: 29672985 [TBL] [Abstract][Full Text] [Related]
36. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection. Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797 [TBL] [Abstract][Full Text] [Related]
37. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Curcio F; Franco T; Topa M; Baldassarre C; Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796 [TBL] [Abstract][Full Text] [Related]
38. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872 [TBL] [Abstract][Full Text] [Related]
39. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Soyka M; Zingg C; Koller G; Kuefner H Int J Neuropsychopharmacol; 2008 Aug; 11(5):641-53. PubMed ID: 18205978 [TBL] [Abstract][Full Text] [Related]
40. Males and females differ in response to opioid agonist medications. Jones HE; Fitzgerald H; Johnson RE Am J Addict; 2005; 14(3):223-33. PubMed ID: 16019973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]